Parameter
| Biomarker | Circulating tumor cells (CTCS) | Full name | Circulating Tumor Cells | Molecular Type | Cells |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis, Monitoring | ||
| Disease | Gastric Cancer | Disease Subtypes | / | ||
| Organ | Stomach | Test Sample / Technology Platform | Peripheral blood (immunomagnetic cell sorting, microfluidic chip, flow cytometry) | ||
| Pathobiological Mechanisms | Tumor cells shed from the primary tumor into the peripheral blood carry the molecular characteristics of the primary tumor. The number of CTCS and epithelial-mesenchymal transition (EMT) phenotype are positively correlated with the stage and metastasis risk of gastric cancer, and can dynamically reflect the treatment response and recurrence | ||||
| Clinical Availability Status | Clinical research stage: Most of them are used for clinical research (such as efficacy monitoring and early warning of recurrence), and some centers are used for prognosis evaluation of advanced gastric cancer | ||||
| Notes and Dynamics | The core indicators of liquid biopsy can realize "real-time biopsy", and dynamic monitoring of the number and molecular characteristics of CTC (such as HER2 and PD-L1) can early detect treatment resistance and recurrence. CTC culture combined with drug sensitivity testing is the future direction of individualized treatment | ||||